Navigation Links
Manchester Announces Availability of Chenodal(TM)
Date:12/14/2009

FORT COLLINS, Colo., Dec. 14 /PRNewswire/ -- Manchester Pharmaceuticals, Inc.(TM) announced today the availability of Chenodal(TM) 250 mg (chenodiol tablets). On October 22, 2009, the US Food and Drug Administration (FDA) approved Chenodal, an important therapy for patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

Chenodal prescriptions have started to be dispensed to patients exclusively through Centric Health Resources ("Centric"), a specialty pharmacy company. Centric provides a single point of contact to deliver seamless support for Chenodal including providing necessary information to health care providers, patients and families, assisting with reimbursement and insurance issues, and ensuring that Chenodal reaches the patients who need it as fast and as conveniently as possible. Patients and physicians are encouraged to contact Centric now at 1-866-758-7068 to begin the process of setting up their first order of Chenodal or to obtain more information about Chenodal. Centric Customer Service is available Monday through Friday 7:00 AM to 6:00 PM CST.

"The commercial availability of Chenodal now provides doctors and their patients with a chenodiol product that meets all FDA requirements for product integrity, quality, safety and effectiveness," commented Lloyd Glenn, Manchester's President.

About Manchester:

Manchester Pharmaceuticals, a privately-held specialty pharmaceutical company, is focused on the identification, development and commercialization of new therapeutic modalities to address the special needs of patients with rare diseases. Manchester is actively pursuing the license and acquisition of additional new product opportunities in the rare disease area.



    For more information:
    Lloyd Glenn, President
    970-685-4119
    www.manchesterpharma.com


SOURCE Manchester Pharmaceuticals, Inc.


'/>"/>
SOURCE Manchester Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the 2009 British Pharmaceutical Conference in Manchester, England
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology:
(Date:4/28/2017)... VA (PRWEB) , ... April 28, 2017 , ... The ... volunteer board members and officers for 2017-2018. The annual board election process has been ... on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, ...
(Date:4/28/2017)... ... 28, 2017 , ... From April 30 to May 3, ... will host industry leaders for the annual spring Convention & Expo, called Momentum ... adapt to the issues currently affecting urgent care and on-demand healthcare. , “Momentum ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... responds to and which He does not. Yisrayl says with so many titles and ... true name, but he says with a little Scripture, backed with a lot of research, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, ... through its Nova Skin Sciences division, recently announced the launch of Allumière Antiaging ... the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract ...
(Date:4/28/2017)... MEMPHIS, Tenn. (PRWEB) , ... April 28, 2017 , ... ... VeinViewer® system, today announced an alliance with B. Braun Medical Inc. , a ... central role in patient care with as many as 90 percent of hospital patients ...
Breaking Medicine News(10 mins):